Daniel J Sheward, Pradeepa Pushparaj, Hrishikesh Das, Allison J Greaney, Changil Kim, Sungyong Kim, Leo Hanke, Erik Hyllner, Robert Dyrdak, Jimin Lee, Xaquin Castro Dopico, Pia Dosenovic, Thomas P Peacock, Gerald M McInerney, Jan Albert, Martin Corcoran, Jesse D Bloom, Ben Murrell, Gunilla B Karlsson Hedestam, B Martin Hällberg
Descendants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant now account for almost all SARS-CoV-2 infections. The Omicron variant and its sublineages have spike glycoproteins that are highly diverged from the pandemic founder and first-generation vaccine strain, resulting in significant evasion from monoclonal antibody therapeutics and vaccines. Understanding how commonly elicited antibodies can broaden to cross-neutralize escape variants is crucial. We isolate IGHV3-53, using "public" monoclonal antibodies (mAbs) from an individual 7 months post infection with the ancestral virus and identify antibodies that exhibit potent and broad cross-neutralization, extending to the BA...
May 15, 2024: Cell reports medicine